- Samsung (KS:) Biologicals on offer ADC service in a new dedicated facility
- Extended collaboration reflects successful partnerships and expertise
INCHEON,
Samsung Biology will support a series of LigaChem Biosciences’ ADCs programs of Samsung Biologics’ new dedicated ADC facility. The two companies are already collaborating on ADC programs for the treatment of solid tumors. LigaChem Biosciences is a biotech pioneering research and development of ADC candidates.
“The latest collaboration will be even stronger Samsung Biologics’ capabilities at all stages of ADC development and manufacturing as part of our commitment to deliver safe and high-quality therapeutics to patients,” said
“This collaboration with Samsung Biology will be an important step towards strengthening the supply chain of high-quality ADC drugs and improving the competitiveness of both companies in the global ADC market,” said
Samsung Biologics’ The ADC facility is a segregated suite, with a 500-liter reactor, that supports the development and manufacture of ADC therapies. Building on the company’s track record of expertise in large-scale antibody manufacturing and process engineering, Samsung Biologics’ ADC’s service coverage includes late-stage discovery and conjugatiin.
Samsung Biology also makes active investments through Samsung Life (KS:) Science Fund of biotech companies pioneering ADC linker technologies, toolbox, and protein engineering.
For more information, visit: https://samsungbiologics.com/services/adc
About Samsung Biologics Co., Ltd.
Samsung Biology (KRX: 207940.KS) is a fully integrated, end-to-end CDMO service provider, offering seamless development and manufacturing solutions from cell line development to final aseptic fill/finish as well as laboratory testing support for the biopharmaceutical products we manufacture. Our state-of-the-art facilities are CGMP compliant with bioreactors from small to large scales to serve a variety of client needs. Maximizing operational efficiency and expanding our capabilities in response to the growing needs of biomanufacturing, Samsung Biology offers a combined 604 kL total capacity in Bio Campus I. The company is launching Bio Campus II with the construction of Plant 5, which will be operational in April 2025, which will add 180 kL biomanufacturing capacity. In addition, Samsung Biologics America allows the company to work closer to clients based in
About LigaChem Biosciences
LigaChem Biosciences, Inc. (LCB) is a clinical stage biopharmaceutical company dedicated to discovering and developing new medicines by using medicinal chemistry expertise to make conventional biologics more targeted and potent for the benefit of patients with chronic diseases. unmet medical needs. LCB develops sustainable pipelines in therapeutic areas within antibiotics, anti-fibrotics, oncology, and ADC platform technology. For more information, visit https://ligachembio.com/
Contact Samsung Biologics
[email protected]
LigaChem Biosciences Contact
[email protected]